1. Generics Bulletin
  2. >>Policy & Regulation
  3. >>Regulation

ASBM Hits Back At British Columbia Switching Scheme

 
• By Dave Wallace

Originator-backed lobbying group the Alliance for Safe Biologic Medicines has raised concerns over a biosimilar switching policy recently unveiled by the Canadian province of British Columbia.

Canada
ASBM Has Aimed Its Criticism At The Canadian Province • Source: Shutterstock

British Columbia’s recently-announced initiative to switch patients using biologic drugs to biosimilar equivalents has prompted “concerns” from patients and doctors, according to originator-backed lobbying group the Alliance for Safe Biologic Medicines.

ASBM – which counts among its member partners Amgen, Genentech and the US Biotechnology Innovation Organization brand industry association – labelled the BC government’s policy “an example of ‘non-medical switching’ – switching that results

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation

Tofidence And Tariffs - Organon Discusses Exposure Of Its Biosimilars Business

 
• By Dave Wallace

During Organon’s first-quarter results call, CEO Kevin Ali discussed the exposure of the biosimilars business to US tariffs, as well as pointing to the recent acquisition of Tofidence (tocilizumab-bavi) from Biogen as an opportunity for growth, as the segment saw a double-digit decline.

Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements

 
• By Dave Wallace

As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.

Rage Against The Machine: Generics CEOs Slam Systemic Problems In The US

 
• By Dave Wallace

During the “CEOs Unplugged” panel at the AAM’s annual conference in February, leaders from Sandoz, Lupin and Amneal discussed the various ways in which the US framework is making life difficult for generics and biosimilars.